Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HEBE, A novel chimeric chronokine for ameliorating memory deficits in Alzheimer's disease

  • Esandi Jauregui, Jon|||0000-0001-5529-2686
  • Renault de Barros, Pedro Victor|||0000-0002-5649-3057
  • Capilla López, Maria Dolores|||0000-0002-9483-4887
  • Blanch Garcia, Rebeca|||0000-0001-6726-4084
  • Edo Salvador, Ángel
  • Ramirez-Gómez, David
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Almolda Ardid, Beatriz|||0000-0001-6631-4385
  • Saura, Carlos Alberto
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-β and Tau protein depositions, with treatments focusing on single proteins have shown limited success due to the complexity of pathways involved. This study explored the potential of chronokines -proteins that modulate aging-related processes- as an alternative therapeutic approach. Specifically, we focused on a novel pleiotropic chimeric protein named HEBE, combining s-KL, sTREM2 and TIMP2, guided by bioinformatic analyses to ensure the preservation of each protein's conformation, crucial for their functions. In vitro studies confirmed HEBE's stability and enzymatic activities, even suggesting it has different activities compared to the individual chronokines. In vivo experiments on APP/Tau mice revealed improved learning and memory functions with HEBE treatment, along with decreased levels of phosphorylated Tau and minor effects on amyloid-β levels. These findings suggest that HEBE is as a promising therapeutic candidate for ameliorating memory deficits and reducing pTau in an AD mouse model.